test Browse by Author Names Browse by Titles of Works Browse by Subjects of Works Browse by Issue Dates of Works

Advanced Search
& Collections
Issue Date   
Sign on to:   
Receive email
My Account
authorized users
Edit Profile   
About T-Space   

T-Space at The University of Toronto Libraries >
Journal of Medical Internet Research >
Volume 3 (2001) >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1807/4602

Title: Cyberpharmacies and the role of the US Food And Drug Administration
Authors: Henney, Jane E
Keywords: Commentary
Drug and Narcotic Control
Prescriptions, Drug
Physician's Practice Patterns
United States Food and Drug Administration
Phosphodiesterase Inhibitors
Quality of Health Care
Issue Date: 31-Jan-2001
Publisher: Gunther Eysenbach; Centre for Global eHealth Innovation, Toronto, Canada
Citation: Jane E Henney. Cyberpharmacies and the role of the US Food And Drug Administration. J Med Internet Res 2001;3(1):e3 <URL: http://www.jmir.org/2001/1/e3/>
Abstract: [This item is a preserved copy and is not necessarily the most recent version. To view the current item, visit http://www.jmir.org/2001/1/e3/ ] The sale of consumer products over the Internet has grown rapidly, including the sale of drugs. While the growth in online drug sales by reputable pharmacies is a trend that may provide benefits to consumers, online drug sales also present risks to purchasers and some unique challenges to regulators, law enforcement officials and policy makers. The Food and Drug Administration (FDA or the Agency) is concerned about the public health implications of Internet drug sales, and we are responding to these concerns as part of our overall goal of developing and implementing risk-based strategies to protect public health and safety. Although other products regulated by the Agency, such as medical devices, medical test products, foods, dietary supplements and animal drugs also are sold online, this paper focuses on online drug sales. We discuss the advantages and risks of online drug sales, outline FDA's authority and enforcement activities in this area, and describe new initiatives we are taking to better respond to the regulatory challenges we face.
URI: http://hdl.handle.net/1807/4602
ISSN: 1438-8871
Other Identifiers: doi:10.2196/jmir.3.1.e3
Rights: Copyright (cc) Retained by author(s) under a Creative Commons License: http://creativecommons.org/licenses/by/2.0/
Appears in Collections:Volume 3 (2001)

Files in This Item:

File Description SizeFormat
jmir.html33.35 kBHTMLView/Open

Items in T-Space are protected by copyright, with all rights reserved, unless otherwise indicated.